The DOI matches its Crossref record.
Broad‐spectrum matrix metalloproteinase inhibitor marimastat–induced musculoskeletal side effects in rats
Abstract
Objective: To characterize the clinical and histopathologic changes in a rat model of broad‐spectrum matrix metalloproteinase (MMP)–induced musculoskeletal syndrome (MSS), and to facilitate research into the causes and treatments of MSS in humans. Methods: Male Lewis rats weighing 150–180 gm were administered 10–30 mg of the broad‐spectrum MMP inhibitor marimastat over a 2‐week period via surgically implanted subcutaneous osmotic pumps. The animals were monitored and scored for the onset and severity of MSS, using clinical and histologic parameters. Results: Marimastat‐treated rats exhibited various clinical signs, including compromised ability to rest on their hind feet, high‐stepping gait, reluctance or inability to move, and hind paw swelling. Histologically, marimastat‐treated rat joints were characterized by soft tissue and bone changes, such as increased epiphyseal growth plate, synovial hyperplasia, and increased cellularity in the joint capsule and extracapsular ligaments. The severity of MSS, as judged by clinical criteria (2 blinded observers using 3 clinical parameters), paw volume, and histologic score, was nearly identical. The observed changes were indistinguishable from those reported for primate models and mimic MSS in humans. Conclusion: This simple and sensitive model of MSS is an attractive alternative for studying the pathology of MSS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Spinale, F. G. (2007) · Physiological Reviews · doi:10.1152/physrev.00012.2007 · Cited by 1,120
Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease
Wang, X., & Khalil, R. A. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.08.002 · Cited by 754
Overview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis
Hu, Q., & Ecker, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041742 · Cited by 475
Breaching the basement membrane: who, when and how?
Rowe, R. G., & Weiss, S. J. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.007 · Cited by 443
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery
Peterson, J. T. (2004) · Heart Failure Reviews · doi:10.1023/b:hrev.0000011395.11179.af · Cited by 370
Osteochondral alterations in osteoarthritis
Suri, S., & Walsh, D. A. (2012) · Bone · doi:10.1016/j.bone.2011.10.010 · Cited by 331
Jacobsen, J. A., Major Jourden, J. L., Miller, M. T., & Cohen, S. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.08.006 · Cited by 313
MMPs as therapeutic targets—Still a viable option?
FINGLETON, B. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2007.06.006 · Cited by 279
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Recent advances in MMP inhibitor design
Fisher, J. F., & Mobashery, S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7894-9 · Cited by 215
Greaves, P. (2012) · Histopathology of Preclinical Toxicity Studies · doi:10.1016/b978-0-444-53856-7.00002-6 · Cited by 5
Metadata
- Authors
- Renkiewicz, R., Qiu, L., Lesch, C., Sun, X., Devalaraja, R., Cody, T., Kaldjian, E., Welgus, H., & Baragi, V.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-06
- Volume
- 48
- Issue
- 6
- Pages
- 1742-1749
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1969123415
- Cited by
- 171
- References
- 0
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.